Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Lineage Cell Therapeutics In (LCTX)

127 + Investors. Track Smart Money conviction in LCTX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +8
Streak
2Q ▲
Buyers last Q
58%

Smart Money Signals — LCTX

Based on 128 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added LCTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
128 hedge funds hold LCTX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
〰️

Stable — ownership unchanged year-over-year

fund count last 6Q
The number of hedge funds holding LCTX is almost the same as a year ago (+4 funds, +3% change). No significant rush to buy or sell — institutional backing is holding steady.
🟡

Slight buying edge — 58% buying

60 buying44 selling
Last quarter: 60 funds bought or added vs 44 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~24 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 37 → 17 → 25 → 24. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 23% medium ■ 26% new
66 out of 128 hedge funds have held LCTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~24 new funds/quarter

19 → 37 → 17 → 25 → 24 new funds/Q
New funds entering each quarter: 37 → 17 → 25 → 24. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 62% veterans vs 29% newcomers

■ 62% veterans ■ 9% 1-2yr ■ 29% new
Entry-cohort mix of 131 holders: 81 (62%) are 2+ year veterans, 12 entered 1–2 years ago, and 38 (29%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 16% AUM from top-100

16% from top-100 AUM funds
24 of 128 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.7
out of 10
Low Exit Risk
Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — LCTX

In 2026 Q1, 60 hedge funds were net buyers of LCTX (24 opened a new position, 36 added to an existing one), while 44 reduced or exited (28 trimmed, 16 sold completely) — a 58% buyer ratio, indicating a slight buying edge. Net buying has persisted for two consecutive quarters, a positive momentum signal. Net fund flow last quarter: +8 funds (more new holders than closures). Total institutional holders: 128.

Hedge Fund Ownership: LCTX

How many hedge funds hold LCTX — quarterly history vs. share price
Quarterly hedge fund ownership of LCTX vs. share price

Market Analysis: LCTX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: LCTX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Lineage Cell Therapeutics In (LCTX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much LCTX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
LCTX
-19.1%
XLV
+5.5%

LCTX outperformed XLV by -24.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
LCTX
+0.0%
XLV
+0.0%

Since the filing became public, LCTX outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

12 top-rated funds 0 high-conviction
Consensus
4.8
/ 10
breadth
×
Elite
0.7
/ 10
conviction
Hedge Fund Positioning: LCTX
2026 Q2 Stats Unlock in 4 days 127 + Investors

Track Smart Money conviction in LCTX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 127 119 6.72%
13F Shares 112M 97M 14.94%
Total Value $176M $169M 4.5%
New Positions 23 25 -2
Increased Positions 35 30 +5
Closed Positions 15 15 -
Reduced Positions 27 26 +1
Total Calls 2 2 -
Total Puts 1 2 -50.0%
PUT/CALL Ratio 0.5 1.0 Bullish

Statistics: LCTX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

127 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in LCTX. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 LCTX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Broadwood Capital Inc 3.39% 49,560,992 $64.9M
2 Defender Capital, LLC. 2.81% 6,598,899 $8.6M
3 Red Crane Wealth Management, LLC 0.58% 597,263 $782K
4 Aster Capital Management (DIFC) Ltd 0.05% 218,241 $198K
5 McMillan Office, Inc. 0.03% 216,000 $283K
6 Beirne Wealth Consulting Services, LLC 0.01% 45,000 $59K
7 Piscataqua Savings Bank 0.01% 12,499 $16K
8 Fifth Third Bancorp 0.01% 4,600,000 $6.0M
9 Trust Co of Toledo NA /Oh/ 0.01% 83,795 $110K
10 Founders Capital Management 0.01% 16,000 $21K
11 ELCO Management Co., LLC 0.01% 15,000 $20K
12 Farrow Financial, Inc. 0.01% 10,646 $14K
13 State of Wyoming 0.01% 43,879 $57K
14 Bridgeway Capital Management, LLC 0.01% 221,000 $290K
15 Flputnam Investment Management Co 0.00% 304,562 $399K
16 Chapin Davis, INC. 0.00% 20,029 $26K
17 Two Sigma Securities, LLC 0.00% 37,793 $50K
18 Lazari Capital Management, INC. 0.00% 10,500 $14K
19 United Bank 0.00% 21,170 $28K
20 SkyOak Wealth, LLC 0.00% 15,000 $20K
21 Lafayette Investments, Inc. 0.00% 13,000 $17K
22 Quadrant Private Wealth Management, LLC 0.00% 10,000 $13K
23 Allegheny Financial Group 0.00% 20,000 $26K
24 Elgethun Capital Management 0.00% 15,000 $20K
25 Beverly Hills Private Wealth, LLC 0.00% 10,000 $13K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Lineage Cell Therapeutics In (LCTX)

What does the Smart Money Trend signal show for LCTX?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added LCTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for LCTX?

Slight buying edge — 58% buying: Last quarter: 60 funds bought or added vs 44 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for LCTX holders?

Smaller funds dominant — 16% AUM from top-100: 24 of 128 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held LCTX?

52% of holders stayed for 2+ years: 66 out of 128 hedge funds have held LCTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Lineage Cell Therapeutics In (LCTX) following the 2026 Q2 hedge fund 13F filings?

As of today, LCTX has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), LCTX has gained -19.1% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →